HDAC (Histone Deacetylases) are a group of enzymes that allow histones to more tightly wrap the DNA by removing acetyl groups (O=C-CH3) from -N-acetyl lysine amino acids. This is significant because DNA is wrapped around histones and that acetylation and de-acetylation control how DNA is expressed. In contrast to histone acetyltransferase, it acts differently. Since non-histone proteins are also among their targets, HDAC proteins are now also referred to as lysine deacetylases (KDAC) in order to better reflect their mode of action. The histone deacetylases are members of the ancient protein superfamily known as the histone deacetylase superfamily, along with the acetylpolyamine amidohydrolases and the acetoin utilization proteins.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V81134 | PI3Kα/HDAC6-IN-1 | PI3Kα/HDAC6-IN-1 (compound 21j) is a dual (bifunctional) inhibitor of PI3Kα/HDAC6 with IC50 of 2.9 and 26 nM respectively. | |
|
V0276 | Pracinostat (SB939) | 929016-96-6 | Pracinostat (formerly SB-939) is a novel, potent and orally bioavailable pan-HDAC (histone deacetylase) inhibitor with potential anticancer activity. |
|
V4578 | PTACH (NCH-51) | 848354-66-5 | PTACH (also known as NCH-51), a SAHA analog, is a novel and potent inhibitor of human histone deacetylase (HDAC). |
|
V76572 | QTX125 TFA | QTX125 TFA is a potent and selective HDAC6 inhibitor. | |
|
V0287 | Quisinostat (JNJ-26481585) | 875320-29-9 | Quisinostat (formerly JNJ26481585) is an orally bioavailable, 2nd generation, hydroxamate-based inhibitor of histone deacetylase (HDAC) with potential anticancer activity. |
|
V0285 | Resminostat (RAS2410) | 864814-88-0 | Resminostat (formerly RAS-2410; 4SC-201) is a potent inhibitor of classes I and II HDACs (histone deacetylases) such as HDAC1/3/6 with potential anticancer activity. |
|
V0273 | RG2833 (RGFP109) | 1215493-56-3 | RG-2833 (formerly RGFP-109) is a potent, selective and brain-permeable inhibitor of HDAC (histone deacetylase) with potential neuroprotective effects. |
|
V0272 | RGFP966 | 1357389-11-7 | RGFP966 (RGF-P966) is a novel, potent and highly selective inhibitor of HDAC3 (histone deacetylase 3) with potential anticancer activity. |
|
V0271 | Rocilinostat (ACY1215; Ricolinostat) | 1316214-52-4 | Rocilinostat (formerly Ricolinostat; ACY-1215), an investigational drug, is a potent, orally bioavailable and selective HDAC6 inhibitor with potential anticancer activity. |
|
V0261 | Romidepsin (FK228, FR901228, Depsipeptide, NSC630176) | 128517-07-7 | Romidepsin (formerly FK-228, FR-901228, Depsipeptide, NSC-630176; trade name Istodax) is a novel, potent and naturally occuring bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with potential anticancer activity. |
|
V0274 | Scriptaid (GCK-1026; Scriptide) | 287383-59-9 | Scriptaid (formerly GCK1026; Scriptide) is a novel and potent histone deacetylase (HDAC) inhibitor with potential anticancer activity. |
|
V79690 | SGC-UBD253 | SGC-UBD253 is a potent HDAC6-UBD antagonist. | |
|
V81398 | SIRT6-IN-3 | SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50 is 7.49 μM). | |
|
V5045 | SIS17 | 2374313-54-7 | SIS17 is a novel, potent and isoform-selective inhibitor of mammalian histone deacetylase 11 (HDAC 11) with an IC50value of 0.83 μM. |
|
V5226 | SKLB-23bb | 1815580-06-3 | SKLB-23bb (HDAC6-IN-1; 23bb) is a novel, potent,orally bioavailable and selective inhibitor forhistone deacetylase 6 (HDAC6) with anticancer, anti-mitotic/antitubulin and neuroprotective effects. |
|
V0284 | Sodium Phenylbutyrate (4-PBA sodium) | 1716-12-7 | Sodium phenylbutyrate (4-Phenylbutyric acid sodium; 4-PBA sodium),an orphan drug marketed by Ucyclyd Pharma, is a novel and potent histone deacetylase (HDAC) inhibitor used as an as adjunctive therapy for chronic treatment of urea cycle disorders involving deficiencies of argininosuccinic acid synthetase (AS), ornithine transcarbamylase (OTC), or carbamylphosphate synthetase (CPS). |
|
V0292 | Tacedinaline (GOE-5549, PD-123654, CI-994; Acetyldinaline) | 112522-64-2 | Tacedinaline (GOE5549, PD123654, CI994; Acetyldinaline) is a potent, orally bioavailable and selective inhibitor of histone deacetylase 1/3 (HDAC1/3) with potential anticancer activity. |
|
V0268 | Tasquinimod (ABR-215050; TASQ) | 254964-60-8 | Tasquinimod (also known as ABR215050),aquinoline-3-carboxamide linomide analogue and an investigational drug, is a novel, and orally bioactive anti-angiogenic agent which potently inhibits HDAC4 allosterically with with potential anticancer activity. |
|
V2762 | TMP195 | 1314891-22-9 | TMP195 (TMP-195) is a first-in-class and selective inhibitor of class II a histone deacetylase (HDAC) with anticancer and immunomodulatory effects. |
|
V0269 | TMP269 | 1314890-29-3 | TMP269 is a novel, potent, selective inhibitor of class IIa HDAC(4/5/7/9) with potential anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
